$0.65 Earnings Per Share Expected for Integra Lifesciences Holdings Corp (NASDAQ:IART) This Quarter

Equities analysts expect that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report $0.65 earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have issued estimates for Integra Lifesciences’ earnings. The lowest EPS estimate is $0.64 and the highest is $0.67. Integra Lifesciences posted earnings of $0.59 per share during the same quarter last year, which would indicate a positive year over year growth rate of 10.2%. The firm is expected to issue its next earnings report on Wednesday, October 30th.

According to Zacks, analysts expect that Integra Lifesciences will report full-year earnings of $2.73 per share for the current year, with EPS estimates ranging from $2.70 to $2.75. For the next year, analysts anticipate that the business will post earnings of $3.03 per share, with EPS estimates ranging from $2.95 to $3.09. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.65 by $0.08. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The company had revenue of $383.60 million for the quarter, compared to analyst estimates of $373.29 million. During the same period last year, the company posted $0.60 earnings per share. The firm’s revenue was up 4.8% compared to the same quarter last year.

A number of analysts have recently issued reports on the company. BTIG Research set a $70.00 target price on Integra Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Zacks Investment Research raised Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 target price on the stock in a research report on Monday, September 2nd. Wells Fargo & Co lifted their target price on Integra Lifesciences from $55.00 to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, July 25th. ValuEngine lowered Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Finally, BidaskClub lowered Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $62.67.

NASDAQ:IART traded down $0.47 during mid-day trading on Monday, hitting $61.40. The company had a trading volume of 367,778 shares, compared to its average volume of 502,058. The business has a fifty day simple moving average of $61.45 and a 200-day simple moving average of $55.12. The company has a current ratio of 2.76, a quick ratio of 1.82 and a debt-to-equity ratio of 0.99. Integra Lifesciences has a 1 year low of $42.14 and a 1 year high of $66.41. The firm has a market capitalization of $5.37 billion, a price-to-earnings ratio of 25.37, a PEG ratio of 1.97 and a beta of 1.10.

In related news, major shareholder Richard E. Caruso sold 80,000 shares of the business’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $61.77, for a total value of $4,941,600.00. Following the completion of the sale, the insider now directly owns 134,134 shares of the company’s stock, valued at $8,285,457.18. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Glenn Coleman sold 3,650 shares of the business’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $55.00, for a total value of $200,750.00. Following the completion of the sale, the chief operating officer now directly owns 25,160 shares of the company’s stock, valued at $1,383,800. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 371,571 shares of company stock worth $22,617,425. Corporate insiders own 4.50% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Boston Partners increased its holdings in Integra Lifesciences by 1.3% in the second quarter. Boston Partners now owns 13,119 shares of the life sciences company’s stock valued at $733,000 after buying an additional 171 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its holdings in Integra Lifesciences by 1.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 13,080 shares of the life sciences company’s stock valued at $731,000 after buying an additional 190 shares during the last quarter. Zions Bancorporation N.A. increased its holdings in Integra Lifesciences by 5.9% in the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock valued at $243,000 after buying an additional 242 shares during the last quarter. LPL Financial LLC increased its holdings in Integra Lifesciences by 4.4% in the second quarter. LPL Financial LLC now owns 5,754 shares of the life sciences company’s stock valued at $319,000 after buying an additional 242 shares during the last quarter. Finally, Advisor Group Inc. increased its holdings in Integra Lifesciences by 0.9% in the first quarter. Advisor Group Inc. now owns 30,842 shares of the life sciences company’s stock valued at $1,719,000 after buying an additional 282 shares during the last quarter. 81.91% of the stock is owned by hedge funds and other institutional investors.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.